Company / Operating Cash Flow per Share
Inhibikase Therapeutics, Inc. Operating Cash Flow per Share History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.92
FY2024
5-year range
-$4.11 / -$0.11
FY2021-FY2024
Trend
+28.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share returned to growth in FY2024 after 2 years of decline, reaching $-2.92.
Based on SEC 10-K filings.
-2.92 in FY2024.
Declined from $-0.57 to $-2.92 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating cash flow per share increased 28.8% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.92 | +28.8% |
| FY2023 | -$4.11 | -622.7% |
| FY2022 | -$0.57 | -405.8% |
| FY2021 | -$0.11 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026